Abcam, ab219650, Anti-PRAME antibody [EPR20330]

Size: 20µL / 100µL / 1mL
Anti-PRAME antibody [EPR20330] (ab219650) is a rabbit monoclonal antibody detecting PRAME in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IP, IHC-P, ICC/IF . Suitable for Human . - Clone EPR20330 is the most cited clone to PRAME - Biophysical QC for unrivalled batch-batch consistency - Over 20 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20330,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, ICC/IF, IP, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:PRAME is expressed in malignant cells, including leukaemias, Hodgkin's lymphoma, breast cancer, and primary and metastatic melanomas.

Product details:
Anti-PRAME antibody [EPR20330] (ab219650) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P, IP and WB.
Abcam's high quality manufacturing and validation processes ensure Anti-PRAME antibody [EPR20330] (ab219650) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-PRAME antibody [EPR20330] (ab219650) specifically detects PRAME (UniProt ID: P78395; Molecular weight: 58kDa) and is sold in 100 µL and 1 mL selling sizes.
Conjugation-ready, carrier free format available for antibody clone EPR20330 -
ab232571
Antibody clone EPR20330 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor
555, Alexa Fluor
647, Alexa Fluor
488, Alexa Fluor
ab307626
ab307630
ab307769
ab312896
This top cited antibody is highly specific for PRAME, a protein that is highly expressed in different types of cancers and is involved in cell proliferation and metastasis, as well as the outcomes of patients with cancer.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PRAME or Preferentially Expressed Antigen in Melanoma is a cancer/testis antigen with a molecular mass of approximately 57 kDa. The PRAME protein is expressed in various tumors including melanoma and shows limited expression in normal adult tissues. Researchers use Monoclonal Antibody EPR20330 to detect PRAME due to its specificity and reliability in applications like PRAME immunohistochemistry (IHC).
Biological function summary
The PRAME protein influences cell proliferation and apoptosis by acting as a repressor of retinoic acid signaling. It is not part of a large complex but interacts with proteins involved in retinoic acid pathways. PRAME inhibits retinoic acid receptor signaling leading to disrupted cell differentiation and survival which is advantageous for cancer cells.
Pathways
Studies show the involvement of PRAME in important cellular processes. It plays a significant role in the retinoic acid pathway and interacts with retinoic acid receptors RAR and RXR. By inhibiting these receptors PRAME affects the transcriptional activity and cellular responses typically mediated by retinoic acid contributing to tumor growth and cancer cell survival.
PRAME expression correlates with aggressive forms of melanoma and various other malignancies such as lung cancer. The presence of PRAME serves as a marker for poor prognosis and can indicate a more invasive cancer phenotype. In melanoma PRAME interacts with proteins related to the disease's progression further emphasizing its importance as a target for therapeutic strategies.